Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III

References

• Lindenbach BD, Murray CL, Thiel HJet al.Flaviviridae. In: Knipe DM, editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2013; p712–746.
   Google Scholar
• Dick GWA, Kitchen SF, Haddow AJ.Zika virus (I). Isolations and serological specificity. Trans R Soc Trop Med Hygiene 1952;46: 509–520.
   PubMed Web of Science ®Google Scholar
• Lazear HM, Diamond MS, Pierson TC.Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J Virol 2016;90: 4864–4875.
   PubMed Web of Science ®Google Scholar
• Duffy Mark R, Tai-Ho C.Zika virus outbreak on Yap Island Federated States of Micronesia. N Engl J Med 2009;360: 2536–2543.
   PubMed Web of Science ®Google Scholar
• Campos GS, Bandeira AC, Sardi SI.Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 2015;21: 1885–1886.
   PubMed Web of Science ®Google Scholar
• Priyamvada L, Quicke KM, Hudson WHet al.Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA 2016;113: 7852–7857.
   PubMed Web of Science ®Google Scholar
• Mlakar J, Korva M, Tul Net al.Zika virus associated with microcephaly. N Engl J Med 2016;374: 951–958.
   PubMed Web of Science ®Google Scholar
• Cao-Lormeau V-M, Blake A, Mons Set al.Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387: 1531–1539.
   PubMed Web of Science ®Google Scholar
• Speer SD, Pierson TC.VIROLOGY. Diagnostics for Zika virus on the horizon. Science 2016;353: 750–751.
   PubMed Web of Science ®Google Scholar
• Marston HD, Lurie N, Borio LLet al.Considerations for developing a Zika virus vaccine. N Engl J Med 2016;375: 1209–1212.
   PubMed Web of Science ®Google Scholar
• Thomas SJ.Zika virus vaccines—a full field and looking for the closers. N Engl J Med 2017;376: 1883–1886.
   PubMed Web of Science ®Google Scholar
• Lazear HM, Stringer EM, de Silva AM.The emerging Zika virus epidemic in the Americas: research priorities. JAMA 2016;315: 1945–1946.
   PubMed Web of Science ®Google Scholar
• Kostyuchenko VA, Lim EX, Zhang Set al.Structure of the thermally stable Zika virus. Nature 2016;533: 425–428.
   PubMed Web of Science ®Google Scholar
• Sirohi D, Chen Z, Sun Let al.The 3.8 resolution cryo-EM structure of Zika virus. Science 2016;352: 467–470.
   PubMed Web of Science ®Google Scholar
• Yu IM, Zhang W, Holdaway HAet al.Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008;319: 1834.
   PubMed Web of Science ®Google Scholar
• Coloma J, Harris E.Broad and strong: the ultimate antibody to dengue virus. Nat Immunol 2015;16: 135–137.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa Set al.A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 2015;16: 170–177.
   PubMed Web of Science ®Google Scholar
• Gallichotte EN, Widman DG, Yount BLet al.A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio 2015;6: e01461–01415.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Purtha WEet al.Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007;81: 12816–12826.
   PubMed Web of Science ®Google Scholar
• Wahala WM, Kraus AA, Haymore LBet al.Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009;392: 103–113.
   PubMed Web of Science ®Google Scholar
• de Alwis R, Smith SA, Olivarez NPet al.Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012;109: 7439–7444.
   PubMed Web of Science ®Google Scholar
• Tsai WY, Lai CY, Wu YCet al.High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol 2013;87: 12562–12575.
   PubMed Web of Science ®Google Scholar
• Lai CY, Tsai WY, Lin SRet al.Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008;82: 6631–6643.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Supasa P, Wongwiwat Wet al.Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol 2016;17: 1102–1108.
   PubMed Web of Science ®Google Scholar
• Zhao H, Fernandez E, Dowd KAet al.Structural basis of Zika virus-specific antibody protection. Cell 2016;166: 1016–1027.
   PubMed Web of Science ®Google Scholar
• Dai L, Song J, Lu Xet al.Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 2016;19: 696–704.
   PubMed Web of Science ®Google Scholar
• Sapparapu G, Fernandez E, Kose Net al.Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 2016;540: 443–447.
   PubMed Web of Science ®Google Scholar
• Barba-Spaeth G, Dejnirattisai W, Rouvinski Aet al.Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 2016;536: 48–53.
   PubMed Web of Science ®Google Scholar
• Ying T, Du L, Ju TWet al.Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014;88: 7796–7805.
   PubMed Web of Science ®Google Scholar
• Gong R, Chen W, Dimitrov DS. Expression, purification, and characterization of engineered antibody CH2 and VH domains. In: Voynov V, Caravella JA, editors. Therapeutic Proteins: Methods and Protocols. Totowa, NJ: Humana Press, 2012; p85–102.
   Google Scholar
• Deng YQ, Zhao H, Li XFet al.Isolation, identification and genomic characterization of the Asian lineage Zika virus imported to China. Sci China Life Sci 2016;59: 428–430.
   PubMed Web of Science ®Google Scholar
• Yu Y, Deng YQ, Zou Pet al.A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat Commun 2017;8: 15672.
   PubMed Web of Science ®Google Scholar
• Cui L, Zou P, Chen Eet al.Visual and motor deficits in grown-up mice with congenital Zika virus infection. EBioMedicine 2017;20: 193–201.
   PubMed Web of Science ®Google Scholar
• Teplyakov A, Obmolova G, Malia TJet al.Structural diversity in a human antibody germline library. MAbs 2016;8: 1045–1063.
   PubMed Web of Science ®Google Scholar
• Ying T, Prabakaran P, Du Let al.Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun 2015;6: 8223.
   PubMed Web of Science ®Google Scholar
• Feng Y, Wang Y, Zhu Zet al.Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. MAbs 2016;8: 799–810.
   PubMed Web of Science ®Google Scholar
• Puligujja P, Balkundi SS, Kendrick LMet al.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials 2015;41: 141–150.
   PubMed Web of Science ®Google Scholar
• Dimitrov DS.Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010;2: 347–356.
   PubMed Web of Science ®Google Scholar
• Throsby M, Geuijen C, Goudsmit Jet al.Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 2006;80: 6982–6992.
   PubMed Web of Science ®Google Scholar
• Beltramello M, Williams KL, Simmons CPet al.The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010;8: 271–283.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang H, Liu Xet al.Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med 2016;8: 369ra179.
   PubMed Web of Science ®Google Scholar
• Austin SK, Dowd KA, Shrestha Bet al.Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 2012;8: e1002930.
   PubMed Web of Science ®Google Scholar
• Dowd KA, DeMaso CR, Pierson TC.Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing. MBio 2015;6: e01559–01515.
   PubMed Web of Science ®Google Scholar
• Shrestha B, Brien JD, Sukupolvi-Petty Set al.The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010;6: e1000823.
   PubMed Web of Science ®Google Scholar
• Lazear HM, Govero J, Smith AMet al.A mouse model of Zika virus pathogenesis. Cell Host Microbe 2016;19: 720–730.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Nie Ket al.Flavivirus NS1 protein in infected host sera enhances viral acquisition by mosquitoes. Nat Microbiol 2016;1: 16087.
   PubMed Web of Science ®Google Scholar
• Aliota MT, Caine EA, Walker ECet al.Characterization of lethal Zika virus infection in AG129 mice. PLoS Negl Trop Dis 2016;10: e0004682.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Ying T, Tao Xet al.Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection. Sci Rep 2016;6: 31629.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Gui M, Niu Xet al.Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep 2016;6: 25856.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Lok SM.The development of therapeutic antibodies against dengue virus. Antiviral Res 2016;128: 7–19.
   PubMed Web of Science ®Google Scholar
• Pierson TC, Fremont DH, Kuhn RJet al.Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008;4: 229–238.
   PubMed Web of Science ®Google Scholar
• Dowd KA, Jost CA, Durbin APet al.A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog 2011;7: e1002111.
   PubMed Web of Science ®Google Scholar
• Crill WD, Roehrig JT.Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001;75: 7769–7773.
   PubMed Web of Science ®Google Scholar
• Poggianella M, Slon Campos JL, Chan KRet al.Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes. PLoS Negl Trop Dis 2015;9: e0003947.
   PubMed Web of Science ®Google Scholar
• Li XQ, Qiu LW, Chen Yet al.Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design. J Gen Virol 2013;94: 2191–2201.
   PubMed Web of Science ®Google Scholar
• Vratskikh O, Stiasny K, Zlatkovic Jet al.Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog 2013;9: e1003458.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KAet al.Modified mRNA vaccines protect against Zika virus infection. Cell 2017;168: 1114–1125.e1110.
   PubMed Web of Science ®Google Scholar
• Larocca RA, Abbink P, Peron JPet al.Vaccine protection against Zika virus from Brazil. Nature 2016;536: 474–478.
   PubMed Web of Science ®Google Scholar